PBL
MCID: PLS025
MIFTS: 47

Plasmablastic Lymphoma (PBL)

Categories: Blood diseases, Immune diseases, Oral diseases, Rare diseases

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 52 58 71
Immunoblastic Large-Cell Lymphoma 71
Pbl 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C83.3
UMLS via Orphanet 72 C3472614
Orphanet 58 ORPHA289666
UMLS 71 C0079746 C3472614

Summaries for Plasmablastic Lymphoma

NIH Rare Diseases : 52 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma . Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes , and skin. The exact underlying cause of plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection , immunosuppressive therapy). There is currently no standard therapy for plasmablastic lymphoma. Treatment usually consists of chemotherapy with or without radiation therapy and hematopoietic stem cell transplantation .

MalaCards based summary : Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to lymphoma aids related and lymphoma, hodgkin, classic. An important gene associated with Plasmablastic Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are NF-kappaB Signaling and Gastric cancer. The drugs Orange and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 Plasmablastic lymphoma (PBL) is a type of large B-cell lymphoma recognized by the World Health... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
# Related Disease Score Top Affiliating Genes
1 lymphoma aids related 31.3 MYC BCL6
2 lymphoma, hodgkin, classic 31.1 PTPRC MS4A1 BCL6
3 acquired immunodeficiency syndrome 31.0 MYC CD38 BCL6
4 b-cell non-hodgkin lymphoma 30.9 MS4A1 BCL6
5 suppressor of tumorigenicity 3 30.9 MYC CDKN2A
6 lymphosarcoma 30.7 PTPRC BCL6
7 immune deficiency disease 30.6 VDR PTPRC CD38 BCL6
8 multicentric castleman disease 30.5 CD38 BCL6 ABCB1
9 bone lymphoma 30.5 PTPRC BCL6
10 plasma cell neoplasm 30.4 PTPRC MYC CD38 BCL6
11 follicular lymphoma 30.3 MYC MS4A1 BCL6
12 richter's syndrome 30.3 NOTCH1 MYC CD38
13 b-cell lymphoma 30.3 PTPRC PRDM1 MYC MS4A1 CDKN2A BCL6
14 leukemia, chronic lymphocytic 2 30.3 MS4A1 CD38
15 lymphoma, mucosa-associated lymphoid type 30.2 PTPRC MYC BCL6
16 diffuse large b-cell lymphoma 29.8 PTPRC PRDM1 MYC MTOR CDKN2A CD38
17 leukemia, chronic myeloid 29.8 PTPRC MYC CD38 ABCB1
18 plasmacytoma 29.8 PTPRC PRDM1 MYC CDKN2A CD38
19 burkitt lymphoma 29.7 PRDM1 MYC MS4A1 CDKN2A BCL6
20 osteogenic sarcoma 29.6 VDR MYC CDKN2A ABCB1
21 central nervous system lymphoma 29.5 PRDM1 MYC CDKN2A BCL6
22 sarcoma 29.3 PTPRC MYC MUC1 MTOR DES ABCB1
23 myelodysplastic syndrome 29.2 NOTCH1 MYC CDKN2A CD38 ABCB1
24 rhabdomyosarcoma 28.9 PTPRC MYC MTOR DES CDKN2A ABCB1
25 lymphoma 28.9 PTPRC PRDM1 NOTCH1 MYC MUC1 MS4A1
26 acute promyelocytic leukemia 28.8 VDR PTPRC NOTCH1 MYC BCL6 ABCB1
27 leukemia, chronic lymphocytic 28.8 PTPRC NOTCH1 MYC MS4A1 CDKN2A CD38
28 lung cancer susceptibility 3 28.8 NOTCH1 MYC MUC1 MTOR CDKN2A ABCB1
29 glioblastoma multiforme 28.5 VDR NOTCH1 MYC MTOR CDKN2A ABCB1
30 leukemia, acute myeloid 28.1 PTPRC NOTCH1 MYC MTOR CDKN2A CD38
31 lymphoma, non-hodgkin, familial 28.1 PTPRC PRDM1 NOTCH1 MYC MTOR MS4A1
32 mantle cell lymphoma 28.0 PTPRC PRDM1 NOTCH1 MYC MTOR MS4A1
33 myeloma, multiple 26.7 SLAMF7 PTPRC PRDM1 NOTCH1 MYC MUC1
34 caspase 8 deficiency 11.3
35 human herpesvirus 8 10.6
36 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.5 MYC BCL6
37 gallbladder signet ring cell adenocarcinoma 10.5 MYC MUC1
38 paranasal sinus lymphoma 10.5 MYC BCL6
39 kaposi sarcoma 10.5
40 cerebral primitive neuroectodermal tumor 10.5 MYC MUC1
41 appendix lymphoma 10.5 MYC BCL6
42 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.4 PTPRC BCL6
43 epiglottis neoplasm 10.4 PTPRC BCL6
44 heart lymphoma 10.4 PTPRC BCL6
45 human immunodeficiency virus type 1 10.4
46 primary cutaneous anaplastic large cell lymphoma 10.4 PTPRC MUC1
47 hodgkin's lymphoma, nodular sclerosis 10.4 PTPRC BCL6
48 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 MYC CDKN2A
49 lymphoproliferative syndrome 10.4
50 pediatric lymphoma 10.4 MYC BCL6

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:



Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

GenomeRNAi Phenotypes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 DES MTOR MYC NOTCH1 PTPRC

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ABCB1 BCL6 CDKN2A DES MTOR MYC
2 cellular MP:0005384 10.16 BCL6 CD38 CDKN2A DES MTOR MYC
3 hematopoietic system MP:0005397 10.15 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
4 endocrine/exocrine gland MP:0005379 10.1 ABCB1 BCL6 CD38 CDKN2A MTOR MYC
5 homeostasis/metabolism MP:0005376 10.06 ABCB1 BCL6 CD38 CDKN2A DES MTOR
6 immune system MP:0005387 10.03 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
7 digestive/alimentary MP:0005381 9.91 ABCB1 CDKN2A MYC NOTCH1 PTPRC VDR
8 liver/biliary system MP:0005370 9.7 ABCB1 BCL6 CDKN2A MYC NOTCH1 PRDM1
9 muscle MP:0005369 9.56 BCL6 CDKN2A DES MTOR MYC NOTCH1
10 no phenotypic analysis MP:0003012 9.17 ABCB1 BCL6 CDKN2A MTOR MYC PRDM1

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 3
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
7
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
8
Carmustine Approved, Investigational Phase 3 154-93-8 2578
9
Melphalan Approved Phase 3 148-82-3 460612 4053
10
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
11
Acyclovir Approved Phase 3 59277-89-3 2022
12
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
13
Dalteparin Approved Phase 3 9005-49-6
14
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Ofloxacin Approved Phase 3 82419-36-1 4583
17
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Tazobactam Approved Phase 3 89786-04-9 123630
20
Vancomycin Approved Phase 3 1404-90-6 14969 441141
21
Piperacillin Approved Phase 3 66258-76-2 43672
22
Iodine Approved, Investigational Phase 3 7553-56-2 807
23
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
24
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
25
Captopril Approved Phase 3 62571-86-2 44093
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
Ribavirin Approved Phase 3 36791-04-5 37542
28
Palivizumab Approved, Investigational Phase 3 188039-54-5
29
Morphine Approved, Investigational Phase 3 57-27-2 5288826
30
Mercaptopurine Approved Phase 3 50-44-2 667490
31
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
32
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
33
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
34
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
35
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
36
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
37
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
38
Polyestradiol phosphate Approved Phase 3 28014-46-2
39
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
40
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
41
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
42 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
43 Interferon-alpha Phase 3
44 Interferon alpha-2 Phase 3
45 Anesthetics, Dissociative Phase 3
46 Analgesics Phase 3
47 Etoposide phosphate Phase 3
48 Antidotes Phase 3
49 Calcium, Dietary Phase 3
50 interferons Phase 3

Interventional clinical trials:

(show top 50) (show all 542)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
3 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
4 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
5 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
6 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
9 A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
10 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
12 A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
13 RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY ("ATT") VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5 Completed NCT00002565 Phase 3 CHOP regimen;cisplatin;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;idarubicin;ifosfamide;mesna;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
14 Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma Completed NCT00005867 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
15 Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma Completed NCT00003150 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
16 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
17 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
18 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
19 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
20 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
21 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
22 Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
23 A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
24 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
26 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
27 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
28 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
29 SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
30 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
31 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
32 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
33 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
34 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
35 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
36 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
37 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
38 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
39 A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
40 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
41 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
42 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
43 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
44 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
45 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
46 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
47 Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
48 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
49 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
50 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

MalaCards organs/tissues related to Plasmablastic Lymphoma:

40
B Cells, Bone, Bone Marrow, T Cells, Skin, Liver, Lymph Node

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 567)
# Title Authors PMID Year
1
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). 61
32519351 2020
2
Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases. 61
32540222 2020
3
Gastrointestinal Tract Plasmablastic Lymphoma in HIV-Infected Adults: A Histopathological Review. 61
32552168 2020
4
Clinical, pathological and molecular features of plasmablastic lymphoma arising in the gastrointestinal tract: A review and reappraisal. 61
32370987 2020
5
Double-hit plasmablastic lymphoma with malignant pleural effusion and leukaemic presentation. 61
32354657 2020
6
Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. 61
32125468 2020
7
Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients. 61
32471974 2020
8
Plasmablastic Lymphoma Found on Autopsy in a Post-Transplant Patient. 61
32542162 2020
9
An unusual case of plasmablastic lymphoma presenting as dermatomyositis. 61
32477530 2020
10
Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial). 61
32430507 2020
11
Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy. 61
32559556 2020
12
Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. 61
31676312 2020
13
Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report. 61
32382394 2020
14
Hiv-Related Lymphoprolipherative Diseases In The Era Of Combination Antiretroviral Therapy. 61
32294049 2020
15
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. 61
32273478 2020
16
Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. 61
32193629 2020
17
Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease. 61
32083160 2020
18
HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. 61
32269975 2020
19
Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry. 61
32366559 2020
20
Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. 61
31725418 2020
21
A retrospective review of cutaneous lymphoma in Botswana. 61
31647120 2020
22
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. 61
32072672 2020
23
Intraoral plasmablastic lymphoma as a primary oral manifestation: A case report and review of literature. 61
32189913 2020
24
Violaceous nodules in an HIV-positive man. 61
32239893 2020
25
Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections. 61
31904586 2020
26
Epstein-Barr virus-positive plasmacytoma in immunocompetent patients: a diagnostic dilemma. 61
32269699 2020
27
Plasmablastic lymphoma presenting as a brachial artery aneurysm associated with haemodialysis arteriovenous access ligation in a renal transplant patient. 61
31244374 2020
28
Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals. 61
31653979 2020
29
Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin. 61
31909131 2020
30
Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. 61
31725923 2020
31
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
32
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma. 61
31842017 2020
33
High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. 61
31348551 2020
34
Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area. 61
31361906 2020
35
Chronic Lymphocytic Leukemia with Divergent Richter's Transformation into a Clonally Related Classical Hodgkin's and Plasmablastic Lymphoma: A Case Report. 61
32231533 2020
36
AIDS-associated Esophageal Plasmablastic Lymphoma. 61
31887446 2019
37
Lymphoid neoplasms of the oral cavity with plasmablastic morphology-a case series and review of the literature. 61
31494113 2019
38
Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone. 61
31505061 2019
39
Plasmablastic lymphoma of the maxillary sinus. 61
31522367 2019
40
Diverse clinical and histopathologic features of cutaneous post-transplant lymphoproliferative disorders: A presentation of two cases. 61
31144292 2019
41
Non- Hodgkin lymphoma of the lips: A rare entity. 61
31570207 2019
42
Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. 61
30804486 2019
43
Oral lesion as the primary diagnosis of non-Hodgkin's lymphoma: a 20-year experience from an oral pathology service and review of the literature. 61
31286184 2019
44
Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. 61
31377210 2019
45
EBV positive mucocutaneous ulcer with plasmacytic/plasmablastic differentiation and MYC rearrangement: a diagnostic challenge and a mimic of plasmablastic lymphoma. 61
31472984 2019
46
Plasmablastic lymphoma of the rectum, a rare cause of lower gastrointestinal bleeding: A case report. 61
30665721 2019
47
Breast Implant-associated Plasmablastic Lymphoma: A Case Report and Discussion of the Literature. 61
31383476 2019
48
Incorporating Bortezomib in the Management of Plasmablastic Lymphoma. 61
31519607 2019
49
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. 61
31257571 2019
50
HIV/AIDS-related lymphoma: perspective from a regional cancer center in India. 61
31730692 2019

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

Pathways related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.22 PTPRC PRDM1 CD38 BCL6
2
Show member pathways
12.22 NOTCH1 MYC MTOR CDKN2A ABCB1
3
Show member pathways
12.18 NOTCH1 MYC MTOR BCL6
4 11.95 MYC MTOR CDKN2A
5 11.85 NOTCH1 MYC MTOR CDKN2A ABCB1
6 11.84 VDR PRDM1 BCL6
7 11.78 NOTCH1 MYC MTOR
8 11.71 MYC CDKN2A BCL6
9 11.69 MYC MUC1 BCL6
10 11.65 MYC MTOR CDKN2A
11 11.37 PTPRC MS4A1 CD38
12
Show member pathways
11.3 PRDM1 MTOR CDKN2A
13 10.99 PTPRC NOTCH1 MS4A1 CD38
14
Show member pathways
10.91 MYC CDKN2A
15 10.9 MYC CDKN2A
16 10.77 VDR ABCB1
17 10.69 MTOR ABCB1
18 10.67 VDR ABCB1

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 PTPRC NOTCH1 MS4A1 CD38 ABCB1

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.92 VDR PRDM1 NOTCH1 MYC BCL6
2 negative regulation of cell proliferation GO:0008285 9.85 VDR NOTCH1 CDKN2A BCL6
3 regulation of gene expression GO:0010468 9.76 PTPRC PRDM1 NOTCH1 MYC
4 negative regulation of transcription, DNA-templated GO:0045892 9.72 VDR NOTCH1 CDKN2A CD38 BCL6
5 negative regulation of gene expression GO:0010629 9.71 VDR PRDM1 NOTCH1 MYC
6 B cell receptor signaling pathway GO:0050853 9.65 PTPRC MS4A1 CD38
7 negative regulation of cell-matrix adhesion GO:0001953 9.54 CDKN2A BCL6
8 positive regulation of glial cell proliferation GO:0060252 9.51 MYC MTOR
9 positive regulation of keratinocyte differentiation GO:0045618 9.49 VDR NOTCH1
10 energy reserve metabolic process GO:0006112 9.43 MYC MTOR
11 B cell differentiation GO:0030183 9.43 PTPRC MS4A1 BCL6
12 somatic stem cell division GO:0048103 9.37 NOTCH1 CDKN2A
13 positive regulation of B cell proliferation GO:0030890 9.33 PTPRC CD38 BCL6
14 cell cycle arrest GO:0007050 9.26 NOTCH1 MYC MTOR CDKN2A
15 positive regulation of gene expression GO:0010628 9.1 VDR PRDM1 NOTCH1 MYC MTOR CDKN2A

Molecular functions related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.55 VDR PRDM1 NOTCH1 MYC BCL6
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.35 PRDM1 NOTCH1 MYC MUC1 BCL6
3 chromatin DNA binding GO:0031490 8.8 PRDM1 NOTCH1 BCL6

Sources for Plasmablastic Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....